What is ARTMS?
ARTMS is a key player in the production and supply of QUANTM targets, enabling local cyclotrons to generate critical isotopes vital for patient care, particularly in Oncology and Cardiology. Their proprietary technology aims to decentralize isotope production, reducing dependence on centralized facilities and ensuring the timely availability of essential isotopes like Gallium-68. The company is dedicated to advancing human health through leadership in medical isotope manufacturing, offering solutions that integrate seamlessly with existing cyclotron infrastructure. ARTMS actively collaborates with drug innovators and distributors to address the escalating demand for impactful nuclear medicine products.
How much funding has ARTMS raised?
ARTMS has raised a total of $22M across 2 funding rounds:
Private Equity
$3M
Series A
$19M
Private Equity (2017): $3M with participation from GF Securities and Quark Venture Inc.
Series A (2020): $19M led by Deerfield Communications Inc, Quark Venture, and GF Securities Co. Ltd
Key Investors in ARTMS
Quark Venture
Quark Venture LP is a venture capital company focused on equity financing of innovative biotechnology companies with breakthrough technology platforms. The company's strategic goal is to continually support such entrepreneurial biotechnology companies to efficiently improve the technology platform and obtain high-growth value by providing diversified healthcare products or services. Quark's proven success is achieved through long-term relationships with target companies that share similar technology innovation visions.
GF Securities
GF Securities Co. Ltd is a financial services company that provides a range of investment banking, brokerage, and asset management services. Their involvement suggests a strategic interest in companies with strong growth potential and innovative business models within the healthcare sector.
Deerfield Communications Inc
Deerfield Communications Inc is an undisclosed investor participating in the funding round, indicating a strategic interest in ARTMS's innovative approach to medical isotope production.
What's next for ARTMS?
The substantial enterprise-level capital infusion positions ARTMS for accelerated growth and market expansion. This strategic investment is expected to fuel further research and development into novel isotope production technologies, enhance manufacturing capabilities, and broaden the company's commercial reach. ARTMS is poised to solidify its leadership in the medical isotope market, driving innovation and improving access to critical diagnostic and therapeutic agents for patients worldwide.
See full ARTMS company page
